leisure time -WSS

leisure time

author：entertainment 2025-09-28 01:30:57 - browse：8692

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： U.S. death rates show how politics are affecting public health

WSS

Asahi Kasei to buy Calliditas, picking up kidney disease drug

U.S. death rates show how politics are affecting public health

Achieving telehealth equity for people with hearing loss

Senate panel passes drug pricing bills, but drops one PBM reform

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

hotspot

leisure time

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.S. death rates show how politics are affecting public health

Virginia high school admissions case could be legal follow

FDA approves first new drug developed for postpartum depression

United colonoscopy coverage change 'may cost lives,' doctors say

Medical students need to learn the potent medicine of empathy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

focus

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

The thinking behind the controversial eating disorder chatbot Tessa

Xenotransplantation trials will require adjusting expectations, experts say

FDA approves first new drug developed for postpartum depression

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Asahi Kasei to buy Calliditas, picking up kidney disease drug

focus

entertainment

explore

explore